Multicenter observational study of fulvestrant 500 mg in postmenopausal Japanese women with ER positive advanced or recurrent breast cancer after prior endocrine treatment (SBCCSG29 study)

被引：0
|
作者：
Kimizuka, K. [1 ]
Inoue, K. [2 ]
Nagai, S. [2 ]
Saito, T. [3 ]
Nakano, S. [4 ]
Futsuhara, K. [5 ]
Sakurai, T. [6 ]
Yamada, H. [7 ]
Hata, S. [8 ]
Kaneko, S. [9 ]
Kurosumi, M. [10 ]
机构：
[1] Kasukabe Municipal Hosp, Dept Breast Surg, Kasukabe, Japan
[2] Saitama Canc Ctr, Dept Breast Oncol, Saitama, Japan
[3] Saitama Red Cross Hosp, Dept Breast Surg, Saitama, Japan
[4] Kawaguchi Municipal Med Ctr, Dept Surg, Kawaguchi, Japan
[5] Jichi Med Univ, Saitama Med Ctr, Div Breast Oncol, Dept Surg, Saitama, Japan
[6] JCHO Saitama Med Ctr, Dept Surg, Saitama, Japan
[7] Sekishindo Hosp, Dept Surg, Kawagoe, Saitama, Japan
[8] Mitsui Hosp, Dept Breast Surg, Kawagoe, Saitama, Japan
[9] Saitama Cooperat Hosp, Dept Surg, Kawaguchi, Saitama, Japan
[10] Saitama Canc Ctr, Dept Pathol, Saitama, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
57PD
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [1] Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study)
    Kimizuka, Kei
    Inoue, Kenichi
    Nagai, Shigenori E.
    Saito, Tsuyoshi
    Nakano, Satoko
    Futsuhara, Kazushige
    Yamada, Hirofumi
    Kaneko, Shiori
    Sakurai, Takashi
    Hata, Satoshi
    Kurosumil, Masafumi
    JOURNAL OF NIPPON MEDICAL SCHOOL, 2019, 86 (03) : 165 - 171
  • [2] Fulvestrant for the treatment of advanced breast cancer in postmenopausal women: A Japanese study
    Watanabe, T
    Sano, M
    Ohno, S
    Inaji, H
    Nishimura, R
    Shin, E
    Nomura, Y
    Morris, C
    ANTICANCER RESEARCH, 2004, 24 (2C) : 1275 - 1280
  • [3] Endocrine response after prior treatment with fulvestrant (Fasiodex®) in postmenopausal women with advanced breast cancer
    Cheung, K
    Robertson, JFR
    Scott, N
    Owers, R
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S98 - S99
  • [4] Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre
    Cheung, KL
    Owers, R
    Robertson, JFR
    ENDOCRINE-RELATED CANCER, 2006, 13 (01) : 251 - 255
  • [5] Tolerability and efficacy of 500 mg fulvestrant in postmenopausal women with estrogen receptor (ER) plus advanced breast cancer
    Come, S. E.
    Parker, L. M.
    Wulf, G.
    Kuter, I.
    Ryan, P. D.
    Tkaczuk, K.
    Borges, V.
    Kasper, H.
    Gelman, R.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] ECONOMIC EVALUATION OF FULVESTRANT 500MG FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER WHO HAVE PROGRESSED ON ENDOCRINE THERAPY
    Polanco, A. C.
    Salazar, A.
    Soto, H.
    Pizarro, M.
    VALUE IN HEALTH, 2014, 17 (03) : A87 - A87
  • [7] Efficacy of fulvestrant 500 mg in Japanese postmenopausal advanced/recurrent breast cancer patients and factors associated with prolonged time-to-treatment failure
    Araki, Kazuhiro
    Ishida, Naoko
    Horii, Rie
    Takahashi, Shunji
    Akiyama, Futoshi
    Ito, Yoshinori
    Ohno, Shinji
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (17) : 2561 - 2568
  • [8] Safety and tolerability of fulvestrant high-dose (500 mg) in postmenopausal women with hormone receptor positive advanced breast cancer
    Gottschalk, N.
    Kuter, I.
    Robertson, J. F.
    Ellis, M. J.
    Lindeman, J.
    Schrader, I.
    Gerber, B.
    Costa, S. D.
    Harbeck, N.
    EJC SUPPLEMENTS, 2009, 7 (02): : 284 - 285
  • [9] Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
    Howell, A
    Robertson, JFR
    Albano, JQ
    Aschermannova, A
    Mauriac, L
    Kleeberg, UR
    Vergote, I
    Erikstein, B
    Webster, A
    Morris, C
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) : 3396 - 3403
  • [10] Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer
    Di Leo, Angelo
    Jerusalem, Guy
    Petruzelka, Lubos
    Torres, Roberto
    Bondarenko, Igor N.
    Khasanov, Rustem
    Verhoeven, Didier
    Pedrini, Jose L.
    Smirnova, Iya
    Lichinitser, Mikhail R.
    Pendergrass, Kelly
    Garnett, Sally
    Lindemann, Justin P. O.
    Sapunar, Francisco
    Martin, Miguel
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) : 4594 - 4600
12345